Evoke Pharma Rallies After QOL Agrees to Buy Company for $11/Share

Dow Jones

Nov 04

By Rob Curran

Shares of Evoke Pharma more than doubled after the developer of biotech treatments for gastrointestinal and rare diseases agreed to a buyout from closely held rival QOL Medical for a substantial premium to its Monday closing price.

QOL agreed to buy Evoke for $11 a share in a deal expected to close by the end of the year. QOL said it will fund the transaction with cash on hand.

Shares of Evoke have more than doubled to $10.70 premarket.

Evoke makes a nasal spray approved by the Food and Drug Administration for the treatment of a digestive condition called gastroparesis.

Write to Rob Curran at rob.curran@wsj.com

(END) Dow Jones Newswires

November 04, 2025 09:02 ET (14:02 GMT)

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2580308057"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2580308057\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2580308057?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-04 22:02","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2580308057","market":"sh","top_or_hot":-1,"title":"Evoke Pharma Rallies After QOL Agrees to Buy Company for $11/Share","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  By Rob Curran \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Shares of <a href=\"https://laohu8.com/S/EVOK\">Evoke Pharma</a> more than doubled after the developer of biotech treatments for gastrointestinal and rare diseases agreed to a buyout from closely held rival QOL Medical for a substantial premium to its Monday closing price. \n</p>\n<p>\n  QOL agreed to buy Evoke for $11 a share in a deal expected to close by the end of the year. QOL said it will fund the transaction with cash on hand. \n</p>\n<p>\n  Shares of Evoke have more than doubled to $10.70 premarket. \n</p>\n<p>\n  Evoke makes a nasal spray approved by the Food and Drug Administration for the treatment of a digestive condition called gastroparesis. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Rob Curran at rob.curran@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  November 04, 2025 09:02 ET (14:02 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Evoke Pharma Rallies After QOL Agrees to Buy Company for $11/Share</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nEvoke Pharma Rallies After QOL Agrees to Buy Company for $11/Share\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2025-11-04 22:02</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  By Rob Curran \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Shares of <a href=\"https://laohu8.com/S/EVOK\">Evoke Pharma</a> more than doubled after the developer of biotech treatments for gastrointestinal and rare diseases agreed to a buyout from closely held rival QOL Medical for a substantial premium to its Monday closing price. \n</p>\n<p>\n  QOL agreed to buy Evoke for $11 a share in a deal expected to close by the end of the year. QOL said it will fund the transaction with cash on hand. \n</p>\n<p>\n  Shares of Evoke have more than doubled to $10.70 premarket. \n</p>\n<p>\n  Evoke makes a nasal spray approved by the Food and Drug Administration for the treatment of a digestive condition called gastroparesis. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Rob Curran at rob.curran@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  November 04, 2025 09:02 ET (14:02 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"EVOK","symbol_name":"Evoke Pharma Inc.","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2580308057","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2580308057","pubTimestamp":1762264920,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Shares of Evoke Pharma more than doubled after the developer of biotech treatments for gastrointestinal and rare diseases agreed to a buyout from closely held rival QOL Medical for a substantial premium to its Monday closing price.QOL agreed to buy Evoke for $11 a share in a deal expected to close by the end of the year. QOL said it will fund the transaction with cash on hand.Shares of Evoke have more than doubled to $10.70 premarket.Evoke makes a nasal spray approved by the Food and Drug Administration for the treatment of a digestive condition called gastroparesis.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"EVOK":"Evoke Pharma Inc.","BK4007":"制药"},"translate_title":"QOL同意以每股11美元收购公司后，Evoke Pharma股价上涨","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"EVOK":1.5},"content_text":"By Rob Curran \n\n\n \n\n\n  Shares of Evoke Pharma more than doubled after the developer of biotech treatments for gastrointestinal and rare diseases agreed to a buyout from closely held rival QOL Medical for a substantial premium to its Monday closing price. \n\n\n  QOL agreed to buy Evoke for $11 a share in a deal expected to close by the end of the year. QOL said it will fund the transaction with cash on hand. \n\n\n  Shares of Evoke have more than doubled to $10.70 premarket. \n\n\n  Evoke makes a nasal spray approved by the Food and Drug Administration for the treatment of a digestive condition called gastroparesis. \n\n\n \n\n\n  Write to Rob Curran at rob.curran@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  November 04, 2025 09:02 ET (14:02 GMT)\n\n\n  Copyright (c) 2025 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}